SEARCH:   Advanced

Blood, 3 September 2009, Vol. 114, No. 10, pp. 2060-2067. Prepublished online as a Blood First Edition Paper on June 4, 2009; DOI 10.1182/blood-2008-11-189399. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2008-11-189399v1 114/10/2060    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Google Scholar Articles by Claviez, A. Articles by Schmitz, N. PubMed PubMed Citation Articles by Claviez, A. Articles by Schmitz, N. Related Collections Transplantation Lymphoid Neoplasia Clinical Trials and Observations Related Articles in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation Alexander Claviez1, Carme Canals2, Daan Dierickx3, Jerry Stein4, Isabel Badell5, Andrea Pession6, Stephen Mackinnon7, Shimon Slavin8, Jean-Hugues Dalle9, Manuel Jurado Chacón10, Mahmoud Sarhan11, Robert Francis Wynn12, Meinolf Suttorp13, Giorgio Dini14, Anna Sureda15, Norbert Schmitz16, on behalf of the Lymphoma and Pediatric Diseases Working Parties 1 Department of Pediatrics and Bone Marrow Transplant Unit, University Hospital Schleswig-Holstein, Kiel, Germany; 2 LWP Statistician, Research Institute, Hospital de la Sant Pau, Barcelona, Spain; 3 Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium; 4 Bone Marrow Transplant Unit, Schneider Children's Medical Center of Israel, Petach-Tikva, Israel; 5 Department of Pediatrics, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 6 Oncology-Haematology & Cell Therapy Unit, University of Bologna, Bologna, Italy; 7 Department of Hematology, Royal Free Hospital and School of Medicine, London, United Kingdom; 8 Department of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel; 9 Haematology & Immunology Pediatric Unit, Hôpital Robert Debre, Paris, France; 10 Servicio de Hematologia, Hospital Universitario Virgen de las Nieves, Granada, Spain; 11 Bone Marrow & Stem Cell Transplantation Clinic, King Hussein Cancer Centre, Amman, Jordan; 12 Department of Pediatric Hematology, Royal Manchester Children's Hospital, Manchester, United Kingdom; 13 Department of Pediatrics, University Hospital Carl Gustav Carus, Dresden, Germany; 14 Institute G. Gaslini, Genova, Italy; 15 Clinical Hematology Division, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; and 16 Asklepios Klinik St Georg, Hamburg, Germany Ninety-one children and adolescents 18 years or younger after allogeneic hematopoietic stem cell transplantation (HSCT) for relapsed or refractory Hodgkin lymphoma (HL) were analyzed. Fifty-one patients received reduced intensity conditioning (RIC); 40 patients received myeloablative conditioning (MAC). Nonrelapse mortality (NRM) at 1 year was 21% (± 4%), with comparable results after RIC or MAC. Probabilities of relapse at 2 and 5 years were 36% (± 5%) and 44% (± 6%), respectively. RIC was associated with an increased relapse risk compared with MAC; most apparent beginning 9 months after HSCT (P = .01). Progression-free survival (PFS) was 40% (± 6%) and 30% (± 6%) and overall survival (OS) was 54% (± 6%) and 45% (± 6%) at 2 and 5 years, respectively. Disease status at HSCT was predictive of PFS in multivariate analysis (P < .001). Beyond 9 months, PFS after RIC was lower compared with MAC (P = .02). Graft-versus-host disease did not affect relapse rate and PFS. In conclusion, children and adolescents with recurring HL show reasonable results with allogeneic HSCT. Especially patients allografted in recent years with good performance status and chemosensitive disease show highly encouraging results (PFS: 60% ± 27%, OS: 83% ± 15% at 3 years). Because relapse remains the major cause of treatment failure, additional efforts to improve disease control are necessary. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Articles in Blood Online: Allogeneic transplantation for children and adolescents with Hodgkin lymphoma Norbert Schmitz, Anna Sureda, Giorgio Dini, Alexander Claviez, and on behalf of the Lymphoma and Pediatric Diseases Working Parties Blood 2009 114: 4605-4606. [Full Text] [PDF] Allotransplantation in pediatric HL James Nachman Blood 2009 114: 2008-2009. [Abstract] [Full Text] [PDF] This article has been cited by other articles: N. Schmitz, A. Sureda, G. Dini, A. Claviez, and on behalf of the Lymphoma and Pediatric Diseases W Allogeneic transplantation for children and adolescents with Hodgkin lymphoma Blood, November 12, 2009; 114(20): 4605 - 4606. [Full Text] [PDF] J. Nachman Allotransplantation in pediatric HL Blood, September 3, 2009; 114(10): 2008 - 2009. [Abstract] [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020